Comparison of the diagnostic accuracy of the msln gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum

Disease Markers

Volumn 35, Issue 2, 2013, Pages 119-127

  Creaney, Jenette ^a   Sneddon, Sophie ^a   Dick, Ian M ^a   Dare, Hanne ^a   Boudville, Neil ^a   Musk, Arthur William ^b   Skates, Steven J ^c   Robinson, Bruce W S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN; MESOTHELIN; MSLN PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; GENE PRODUCT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LIMIT OF DETECTION; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882446783     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/874212     Document Type: Article

References (35)

1. B. W. S. Robinson, A. W. Musk, and R. A. Lake, "Malignant mesothelioma, " Lancet, vol. 366, no. 9483, pp. 397-408, 2005.
2. B. W. S. Robinson and R. A. Lake, "Advances in malignant mesothelioma, " New England Journal of Medicine, vol. 353, no. 15, pp. 1591-1603, 2005.
3. N. Yamaguchi, K. Hattori, M. Oh-Eda, T. Kojima, N. Imai, and N. Ochi, "A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPCY5, " Journal of Biological Chemistry, vol. 269, no. 2, pp. 805-808, 1994.
4. T. Kojima, M. Oh-Eda, K. Hattori et al., "Molecular cloning and expression of megakaryocyte potentiating factor cDNA, " Journal of Biological Chemistry, vol. 270, no. 37, pp. 21984-21990, 1995.
5. K. Chang and I. Pastan, "Molecular cloning ofmesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 136- 140, 1996.
6. Z. E.Muminova, T.V. Strong, andD. R. Shaw, "Characterization of human mesothelin transcripts in ovarian and pancreatic cancer, " BMC Cancer, vol. 4, article 19, 2004.
7. N. Scholler, N. Fu, Y. Yang et al., "Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11531-11536, 1999.
8. I. Hellstrom, J. Raycraft, S. Kanan et al., "Mesothelin variant 1 is released from tumor cells as a diagnostic marker, " Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 1014- 1020, 2006.
9. M. Ho, M. Onda, Q. C. Wang, R. Hassan, I. Pastan, and M. O. Lively, "Mesothelin is shed fromtumor cells, " Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 9, article 1751, 2006.
10. J. Creaney and B. W. S. Robinson, "Serum and pleural fluid biomarkers for mesothelioma, " Current Opinion in Pulmonary Medicine, vol. 15, no. 4, pp. 366-370, 2009.
11. J. Creaney, D. Yeoman, Y. Demelker et al., "Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma, " Journal of Thoracic Oncology, vol. 3, no. 8, pp. 851-857, 2008.
12. M. Onda, S. Nagata, M. Ho et al., "Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma, " Clinical Cancer Research, vol. 12, no. 14, pp. 4225-4231, 2006.
13. K. Shiomi, H.Miyamoto, T. Segawa et al., "Novel ELISA system for detection of N-ERC/mesothelin in the sera ofmesothelioma patients, " Cancer Science, vol. 97, no. 9, pp. 928-932, 2006.
14. K. Shiomi, Y. Hagiwara, K. Sonoue et al., "Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker formesothelioma, " Clinical Cancer Research, vol. 14, no. 5, pp. 1431-1437, 2008.
15. K. Iwahori, T. Osaki, S. Serada et al., "Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparisonwithmesothelin, " LungCancer, vol. 62, no. 1, pp. 45-54, 2008.
16. K. Hollevoet, K. Nackaerts, J. Thimpont et al., "Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor inmesothelioma, "American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 620-625, 2010.
17. J. Creaney, D. Yeoman, L. K.Naumoff et al., "Solublemesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma, " Thorax, vol. 62, no. 7, pp. 569-576, 2007.
18. K.Hollevoet, K.Nackaerts, R. Gosselin et al., "Solublemesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma, " Journal ofThoracic Oncology, vol. 6, no. 11, pp. 1930-1937, 2011.
19. K. Hollevoet, J. Van Cleemput, J. Thimpont et al., "Serial measurements of mesothelioma serum biomarkers in asbestosexposed individuals: a prospective longitudinal cohort study, " Journal ofThoracic Oncology, vol. 6, no. 5, pp. 889-895, 2011.
20. K. Hollevoet, K. Nackaerts, O.Thas et al., "The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor, " Chest, vol. 141, no. 2, pp. 477-484, 2012.
21. E. Kagan and A. Brody, "Immunopathology of asbestos-related lung disease, " in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 421-444, Butterworth-Heinemann, Boston, Mass, USA, 1996.
22. J. Spurzem and S. Rennard, "Immunopathology of idiopathic pulmonary fibrosis, " in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 119-132, Butterworth-Heinemann, Boston, Mass, USA, 1996.
23. B. Robinson, "Sarcoidosis, " in Immunopathology of Lung Disease, R. Kradin and B. Robinson, Eds., pp. 165-190, Butterworth- Heinemann, Boston, Mass, USA, 1996.
24. R.W. Light, M. I.Macgregor, P. C. Luchsinger, and W. C. Ball Jr., "Pleural effusions: The diagnostic separation of transudates and exudates, "Annals of InternalMedicine, vol. 77, no. 4, pp. 507-513, 1972.
25. N.Boudville, R. Paul, B.W. S. Robinson, and J. Creaney, "Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening, " Lung Cancer, vol. 73, no. 3, pp. 320-324, 2011.
26. A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, and M. W. Steffes, "National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, " Annals of Internal Medicine, vol. 139, no. 2, pp. 137-147, 2003.
27. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, "Amore accuratemethod to estimate glomerular filtration rate from serum creatinine: a new prediction equation, " Annals of Internal Medicine, vol. 130, no. 6, pp. 461-470, 1999.
28. E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, " Biometrics, vol. 44, no. 3, pp. 837-845, 1988.
29. S.D.West and Y. C. G. Lee, "Management ofmalignant pleural mesothelioma, " Clinics in ChestMedicine, vol. 27, no. 2, pp. 335- 354, 2006.
30. A. Segal, G. F. Sterrett, F.A. Frost et al., "Adiagnosis ofmalignant pleuralmesothelioma can be made by effusion cytology: results of a 20 year audit, " Pathology, vol. 45, no. 1, pp. 44-48, 2013.
31. H. E. Davies, R. S. Sadler, S. Bielsa et al., "Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions, " American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 437-444, 2009.
32. A. Scherpereel, B. Grigoriu, M. Conti et al., "Soluble mesothelin- related peptides in the diagnosis of malignant pleural mesothelioma, " American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 10, pp. 1155-1160, 2006.
33. O. Topalak, U. Saygili, M. Soyturk et al., "Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study, " Gynecologic Oncology, vol. 85, no. 1, pp. 108-113, 2002.
34. B. D. Grigoriu, A. Scherpereel, P. Devos et al., "Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment, " Clinical Cancer Research, vol. 13, no. 10, pp. 2928-2935, 2007.
35. R. Hassan, T. Bera, and I. Pastan, "Mesothelin: a new target for immunotherapy, " Clinical Cancer Research, vol. 10, no. 12, pp. 3937-3942, 2004.